Literature DB >> 17439505

Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features.

P Mathurin1, F Beuzin, A Louvet, N Carrié-Ganne, A Balian, J C Trinchet, D Dalsoglio, S Prevot, S Naveau.   

Abstract

BACKGROUND: Studies using consecutive liver biopsies constitute an attractive approach to gaining insight into the pathogenesis of alcoholic liver disease. AIM: To analyse histological factors at baseline, which are predictive of fibrosis progression and recurrence of alcoholic hepatitis.
RESULTS: A total of 193 drinkers underwent consecutive biopsies at an interval of 4 years. At baseline, 20 had normal livers, 135 steatosis, five fibrosis and 33 alcoholic hepatitis. The fibrosis score increased from 1.07 +/- 0.07 to 1.7 +/- 0.94 (P < 0.001). In multivariate analysis, only steatosis (P = 0.04), alcoholic hepatitis (P = 0.0004) and stage of fibrosis (P < 0.0001) were independent predictive factors of the fibrosis score at the second biopsy. Cirrhosis developed more frequently in patients with steatosis (11%) and alcoholic hepatitis (39%) than in others (0%, P < 0.0001). Alcoholic hepatitis recurred more frequently in patients with alcoholic hepatitis at baseline: 58% vs. 15%, P < 0.0001. In multivariate analysis, alcoholic hepatitis at the first biopsy was the only predictive factor of its recurrence (P < 0.0001).
CONCLUSIONS: In a large cohort of drinkers with consecutive biopsies, steatosis, fibrosis stage and alcoholic hepatitis at baseline were independent predictive factors of fibrosis progression. In terms of mechanisms, we propose a novel concept of multiple hits of alcoholic hepatitis occurring in the same patient.

Entities:  

Mesh:

Year:  2007        PMID: 17439505     DOI: 10.1111/j.1365-2036.2007.03302.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  38 in total

Review 1.  Binge drinking: Burden of liver disease and beyond.

Authors:  Susana Llerena; María Teresa Arias-Loste; Angela Puente; Joaquín Cabezas; Javier Crespo; Emilio Fábrega
Journal:  World J Hepatol       Date:  2015-11-28

Review 2.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Definition, epidemiology and magnitude of alcoholic hepatitis.

Authors:  Sarpreet Basra; Bhupinderjit S Anand
Journal:  World J Hepatol       Date:  2011-05-27

Review 4.  Impact of etiological treatment on prognosis.

Authors:  Chien-Wei Su; Ying-Ying Yang; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2017-07-12       Impact factor: 6.047

Review 5.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  Alcoholic liver disease: mechanisms of injury and targeted treatment.

Authors:  Alexandre Louvet; Philippe Mathurin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

7.  Refining criteria for liver biopsy in severe alcoholic hepatitis: Moving the field forward.

Authors:  Geralyn Palmer; Ashwani K Singal
Journal:  United European Gastroenterol J       Date:  2020-09-01       Impact factor: 4.623

Review 8.  Grand Rounds: Alcoholic Hepatitis.

Authors:  Ashwani K Singal; Alexandre Louvet; Vijay H Shah; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-06-13       Impact factor: 25.083

9.  Underestimation of liver-related mortality in the United States.

Authors:  Sumeet K Asrani; Joseph J Larson; Barbara Yawn; Terry M Therneau; W Ray Kim
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

Review 10.  Management of alcohol misuse in patients with liver diseases.

Authors:  Jennifer L Peng; Milan Prakash Patel; Breann McGee; Tiebing Liang; Kristina Chandler; Sucharat Tayarachakul; Sean O'Connor; Suthat Liangpunsakul
Journal:  J Investig Med       Date:  2016-12-09       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.